SUR2B

Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings

Retrieved on: 
Monday, February 27, 2023
Clinical trial, LOS, AKI, Therapy, Mitochondrion, Kidney, Acute kidney injury, Investigational New Drug, Same, IND, United Kingdom, International Conference on Emerging Infectious Diseases, FDA, KATP, Critical care, Patient, Abstract, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CRRT, Kidney disease, CKD, Drug development, HIV disease progression rates, Conference, Chronic kidney disease, Food, Framework, Pharmaceutical industry, Medical device, Nephrology, SUR2B

LOS ALTOS, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the potential of UNI-494, the Company’s proprietary drug that selectively binds to the SUR2B subunit of the mitochondrial KATP channel, will be the focus of several presentations at two upcoming medical and scientific meetings in March 2023.

Key Points: 
  • Shalabh Gupta, M.D., Chief Executive Officer of Unicycive, will lead a discussion on UNI-494 at the upcoming 5th Annual Chronic Kidney Disease Drug Development Summit taking place in Boston, MA from March 7-9, 2023.
  • Two abstracts were accepted for presentation at the 28th International Conference on Critical Care in Nephrology: the Acute Kidney Injury & CRRT Conference taking place in San Diego, CA from March 29- April 1, 2023.
  • “We are studying UNI-494 in Phase 1 clinical trial in the United Kingdom (UK).
  • We also plan to file a corresponding Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in 2023 for a Phase 2 proof-of-concept trial in acute kidney injury (AKI) patients.”

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

Retrieved on: 
Monday, November 21, 2022
COVID-19, Nicorandil, LOS, Acute kidney injury, Kidney disease, Literature, Kidney, Health care, Liver disease, Safety, Therapy, Degenerative disease, Enzyme, Biotechnology, Patient, Contrast (vision), KATP, Liver, Disease, Randomized controlled trial, Patent, Security (finance), BID, AMD, MHRA, Mitochondrial disease, Geographic atrophy, GA, Failure, Severe cognitive impairment, Medication, Animal, Oxidative stress, Coronavirus, Hyperphosphatemia, FDA, Pharmaceutical industry, SUR2B

LOS ALTOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced key findings of UNI-494 efficacy from a preclinical study in animal models of Geographic Atrophy (GA).

Key Points: 
  • LOS ALTOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced key findings of UNI-494 efficacy from a preclinical study in animal models of Geographic Atrophy (GA).
  • The Company evaluated the effect of UNI-494 in preventing visual function loss in a rat model of GA.
  • The study evaluated four groups (n=8 per group): untreated, vehicle control, low dose of UNI-494, and high dose of UNI-494.
  • Further preclinical studies are planned to investigate these promising findings of the effect of UNI-494 in improving visual function.

Unicycive Announces Third Quarter Financial Results and Provides Business Update

Retrieved on: 
Monday, November 14, 2022
Marketing, AKI, Acute kidney injury, Patent, BE, Medication, Safety, Enzyme, LOS, Partnership, Alcoholic hepatitis, Randomized controlled trial, NDA, MHRA, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dry, Hepatic encephalopathy, Hyperphosphatemia, FDA, United Kingdom, Nephrology, File, CTA, Degenerative disease, Therapy, Dialysis, Pharmacokinetics, IND, Nicorandil, Food, KATP, Liver disease, IgG4-related ophthalmic disease, Oxidative stress, Phosphate binder, Literature, Medicines and Healthcare products Regulatory Agency, New Drug Application, Medicine, Society, Chronic kidney disease, CKD, Kidney disease, Patient, Pharmaceutical industry, Generic drug, Glaucoma, SUR2B

LOS ALTOS, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) --  Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2022, and provided a business update.

Key Points: 
  • The third quarter of 2022 and recent weeks have been particularly productive as we completed enrollment of our pivotal bioequivalence trial of RENAZORB, with topline results expected by year-end.
  • We remain on track to file a New Drug Application (NDA) in 2023, saidShalabh Gupta, M.D., Chief Executive Officer of Unicycive.
  • Dr. Gupta added, We were delighted to share favorable results from both our product candidates with the nephrology community at this years Kidney Week.
  • General and administrative expenses for the quarter ended September 30, 2022 were $1.7 million, compared with $0.9 million for the same quarter in 2021.

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)

Retrieved on: 
Wednesday, September 7, 2022
ADME, Literature, Enzyme, IgG4-related ophthalmic disease, Acute kidney injury, Vance DeGeneres, University, Kidney, Potassium, Safety, Hepatic encephalopathy, Research, Therapy, AKI, Chronic kidney disease, Randomized controlled trial, Hyperphosphatemia, Decision-making, Degenerative disease, Ischemia-reperfusion injury of the appendicular musculoskeletal system, MG, Macular degeneration, KATP, LOS, Kidney disease, RATS, Patent, Alcoholic hepatitis, Liver disease, Animal, GLOBE, Pharmacology, Urine, Nasdaq, Company, Biotechnology, ATP, Nicorandil, AMD, Ischemia, Oxidative stress, Patient, Pharmaceutical industry, Medicine, SUR2B

LOS ALTOS, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced key findings of UNI-494 efficacy from a preclinical study in rodent model of Acute Kidney Injury.

Key Points: 
  • LOS ALTOS, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced key findings of UNI-494 efficacy from a preclinical study in rodent model of Acute Kidney Injury.
  • The Company evaluated the effect of UNI-494 on ischemia-reperfusion induced acute kidney injury (IR-AKI) in rats.
  • We are excited to report this key finding from the IR-AKI model showing treatment with UNI-494 significantly reduced this key biomarker of kidney injury that is a well-accepted biomarker of proximal renal tubule damage.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.For more information, please visit www.unicycive.com .